Caldwell Sutter Capital Inc. Decreases Stake in Danaher Co. (NYSE:DHR)

Caldwell Sutter Capital Inc. lessened its holdings in shares of Danaher Co. (NYSE:DHRFree Report) by 3.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,147 shares of the conglomerate’s stock after selling 100 shares during the quarter. Caldwell Sutter Capital Inc.’s holdings in Danaher were worth $728,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Moneta Group Investment Advisors LLC lifted its holdings in Danaher by 96,490.5% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 23,287,013 shares of the conglomerate’s stock worth $6,180,839,000 after purchasing an additional 23,262,904 shares in the last quarter. Norges Bank bought a new position in shares of Danaher in the fourth quarter worth $2,057,164,000. Wellington Management Group LLP raised its position in shares of Danaher by 18.6% in the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after buying an additional 3,905,449 shares in the last quarter. Harris Associates L P purchased a new position in Danaher during the second quarter worth about $557,074,000. Finally, Allen Investment Management LLC increased its stake in Danaher by 1,440.7% in the 3rd quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock worth $273,009,000 after acquiring an additional 1,028,976 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on DHR shares. JPMorgan Chase & Co. boosted their price objective on Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. The Goldman Sachs Group lowered Danaher from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $215.00 to $205.00 in a research note on Thursday, December 7th. HSBC initiated coverage on shares of Danaher in a research note on Monday, December 18th. They issued a “hold” rating on the stock. Finally, Raymond James raised their price target on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $266.00.

Get Our Latest Stock Report on DHR

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Georgeann Couchara sold 2,622 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,957 shares of company stock worth $8,265,802. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Up 0.4 %

Shares of NYSE:DHR opened at $249.72 on Monday. The firm has a market capitalization of $184.93 billion, a P/E ratio of 39.08, a P/E/G ratio of 3.80 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.68. The stock has a 50 day moving average price of $248.01 and a 200-day moving average price of $230.54. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $259.00.

Danaher (NYSE:DHRGet Free Report) last posted its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business had revenue of $6.41 billion during the quarter, compared to the consensus estimate of $6.10 billion. During the same quarter in the prior year, the company earned $2.87 earnings per share. The firm’s quarterly revenue was down 10.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Danaher Co. will post 7.62 EPS for the current fiscal year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be paid a dividend of $0.27 per share. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 annualized dividend and a yield of 0.43%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is presently 16.90%.

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read More

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.